For the treatment of hidradenitis suppurative (HS), the novel selective inhibitor of interleukin (IL)-17A izokibep is being investigated.
After 12 weeks of treatment, patients with HS who received izokibep therapy reached high grades of HS clinical response (HiSCR). More than 70% of participants achieved HiSCR50 and 33% even reached HiSCR100.
Kim Papp, MD, PhD, FRCPC, presented the single-arm part A of a phase 2b/3 trial at the 2023 American Academy of Dermatology annual meeting, which included 30 patients with moderate-to-severe HS.1 For patients with HS lesions in two or more separate anatomic areas and three or more abscesses or nodules, treatment consisted of 160 mg of izokibep weekly. The randomized clinical part B of the study (N=150) is ongoing.
The participants, with a mean age of 38 (70% women), had a HS diagnosis for a mean of 12.8 years. One-third of patients presented with Hurley stage 3. At week 12, HiSCR50 (ie, a ≥50% reduction from baseline) was present in 71% of patients. HiSCR75 and HiSCR90 were observed in 57% and 38%, respectively, and one-third of patients reached HiSCR100.
No cases of candidiasis were observed up to week 12, and the most common adverse events were injection site reactions. The profile of izokibep coincided with what has already been observed for IL-17A inhibitors.
“One-third [of participants] achieved HiSCR100,” Dr. Papp said. “That is something we have never seen before. An efficacy that high supports further development. Hence, a second phase 3 study has been fast-tracked.”
Copyright ©2023 Medicom Medical Publishers
